A comprehensive resource on case studies of marketed kinase drugs
and promising drug trials
Since the discovery of protein kinase activity in 1954, the
field of protein kinase drug discovery has advanced dramatically.
With the ongoing clinical success of the Bcr-Abl kinase inhibitor
Gleevec in the treatment of chronic myelogenous leukemia and seven
additional marketed kinase inhibitor drugs, researchers have
compelling evidence that kinase inhibitors can be highly
efficacious in the treatment of diseases caused by aberrant
activity of protein kinase. Currently more than 100 protein kinase
inhibitors are in clinical development.
In one comprehensive volume, the editors, Dr. Rongshi Li and Dr.
Jeffrey Stafford, present timely and important case studies of
marketed kinase drugs and several of the most advanced kinase
inhibitors in clinical trials. "Kinase Inhibitor Drugs"
includes:
Case studies from leading investigators and experts in the field
that provide firsthand accounts of kinase inhibitor discovery
Current thinking on kinase structure, biochemistry, and signal
transduction pathways
Information on state-of-the-art technologies and tools such as
structure-based and fragment-based drug discovery
A lineup of clinical-phase growth factor receptor inhibitors
Inhibitors of cell cycle kinases
The discovery of allosteric inhibitors of MEK kinase
Information on pharmacogenomics and its application to kinase
inhibitor clinical development
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!